Form 4: Karyopharm Therapeutics EVP Reshma Rangwala Reports Sale of Shares to Cover Tax Obligations

Reshma Rangwala, EVP & Chief Medical Officer of Karyopharm Therapeutics, sold 3,587 shares of common stock on March 4, 2025, to cover withholding tax liabilities.

Summary

• Reshma Rangwala, EVP & Chief Medical Officer of Karyopharm Therapeutics Inc., reported a sale of 3,587 shares of common stock on March 4, 2025.
• The sale was executed at a weighted average price of $6.29 per share, with individual transactions ranging from $6.11 to $6.31.
• The transaction was conducted under a pre-arranged automatic sale plan adopted on April 4, 2022, to cover withholding tax obligations related to the vesting of restricted stock units.
• Following the reported transaction, Rangwala directly owns 29,272 shares of Karyopharm Therapeutics Inc.

Sentiment

Score: 5

Explanation: The document reports a routine stock sale by an executive for tax purposes, which is neither particularly positive nor negative.

Industry Context

Executive stock sales are a common occurrence and are often related to personal financial planning or tax obligations. The use of a pre-arranged trading plan (Rule 10b5-1) is a standard practice to avoid accusations of insider trading.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale and the relatively small number of shares involved.

Key Dates

Keywords

Karyopharm Therapeutics, Reshma Rangwala, Form 4, Stock Sale, Executive, Securities, Tax Liabilities, Automatic Sale Plan, KPTI